Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "RNAi Therapeutics Market (3rd Edition) by Type of RNAi Molecule, Therapeutic Area, Route of Administration, Key Geographical Regions, Sales Forecast and Leading Industry Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.

The global RNAi therapeutics market is projected to increase from USD 3.6 billion in 2026 to USD 9.1 billion by 2035, representing a compound annual growth rate of approximately 10.8% during the forecast period. Market growth is being supported by regulatory approvals, pipeline maturation, advances in oligonucleotide chemistry and increasing investment in targeted RNA delivery technologies.

RNA interference therapeutics have become a clinically validated precision medicine platform across rare genetic, metabolic, cardiovascular, hepatic, hematological and other disorders. Multiple product approvals and growing commercial adoption have strengthened confidence in the modality, encouraging pharmaceutical and biotechnology companies to expand development programs beyond established liver-directed applications.

RNAi Therapeutics Market Growth Drivers

A steady cadence of regulatory approvals is strengthening physician confidence, improving patient access and expanding the commercial potential of RNAi-based medicines. Recent approvals involving ATTR amyloidosis with cardiomyopathy, hemophilia A or B and familial chylomicronemia syndrome demonstrate the growing relevance of RNAi therapeutics across diverse disease areas.

Advances in chemical modification, conjugation and targeted delivery are also improving potency, stability, tissue uptake and dosing convenience. Next-generation platforms are being developed to reach the central nervous system, kidney, lung, eye and solid tumors, creating potential opportunities beyond hepatic indications. Strategic licensing agreements, platform collaborations and cross-border transactions are further accelerating innovation while distributing development risk among market participants.

Commercial validation remains another important growth catalyst. An approved siRNA therapy for reducing LDL cholesterol has generated more than USD 1 billion in annual sales, highlighting the potential for RNAi products to achieve blockbuster status in large metabolic and cardiovascular markets. Financing activity and manufacturing capacity investments also indicate continued confidence in siRNA- and shRNA-based drug development.

Market Challenges and Emerging Opportunities

Efficient extrahepatic delivery remains a central technical challenge for the RNAi therapeutics market. Developers continue to address tissue-specific targeting, cellular uptake, endosomal escape and sustained gene silencing outside the liver. Long-term delivery data will be an important factor in determining platform adoption, clinical differentiation and future market consolidation.

Additional barriers include off-target activity, immune stimulation, manufacturing scalability, complex chemical modification requirements and premium treatment costs. These factors can extend development timelines and increase regulatory and commercialization expenses. Continued progress in tissue-selective delivery, manufacturing processes and safety evaluation is expected to reduce these constraints through 2035.

RNAi Therapeutics Market Segmentation

By RNAi molecule: siRNA and shRNA
By therapeutic area: oncological, genetic, metabolic, hematological, ophthalmic and other disorders
By route of administration: subcutaneous, intravenous, topical and intradermal
By region: North America, Europe, Asia-Pacific and the rest of the world

The siRNA segment is expected to account for the largest share of the global RNAi therapeutics market, supported by extensive clinical validation, regulatory success and commercial availability. Approved products include Onpattro, Amvuttra, Givlaari, Oxlumo, Leqvio, Qfitlia and Rivfloza. The shRNA segment is projected to record the highest growth rate as interest increases in vector-based approaches designed to support longer-duration gene silencing.

Metabolic disorders currently represent the largest therapeutic-area segment, driven by the adoption of RNAi products targeting lipid metabolism and cardiometabolic risk factors. Oncology is forecast to register the highest CAGR as developers investigate RNAi approaches for cancer-associated genes that remain difficult to address through conventional therapeutic strategies.

Intravenous administration currently accounts for the largest market share due to its compatibility with complex formulations, established infusion-center networks and existing reimbursement pathways. Subcutaneous administration is expected to expand at the fastest rate through 2035, supported by demand for convenient outpatient dosing and less resource-intensive treatment delivery.

Regional RNAi Therapeutics Market Outlook

North America is expected to maintain its global market leadership through 2035. The region benefits from a strong RNAi research ecosystem, established specialty-care infrastructure, significant pharmaceutical investment and a high concentration of companies developing therapies for rare genetic, cardiometabolic, hematological and neurological indications. Investment in domestic siRNA manufacturing capacity is also improving regional supply readiness.

Asia-Pacific is projected to record the highest regional CAGR. Growth is being driven by expanding clinical development activity, next-generation siRNA platforms and increasing participation by Asia-based companies in international licensing agreements. China-based developers are advancing programs across cardiovascular, metabolic, rare disease, central nervous system and viral hepatitis indications.

Competitive Landscape

Prominent companies active in the RNAi therapeutics market include:

Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
Benitec Biopharma
Novo Nordisk
Novartis
OliX Pharmaceuticals
Silence Therapeutics
Sirnaomics

The competitive landscape is increasingly shaped by high-value discovery partnerships, platform licensing arrangements, regional commercialization agreements and investments in manufacturing infrastructure. Artificial intelligence-enabled RNAi discovery collaborations and licensing transactions covering cardiovascular, neurological and metabolic assets reflect sustained strategic interest in the sector.

RNAi Therapeutics Market Report Coverage

The market report evaluates approved products, late-stage candidates and development pipelines by molecule type, target gene, clinical phase, therapeutic area, administration route and regulatory designation. It also examines company competitiveness, clinical trials, patents, scientific publications, partnerships, funding activity, commercialization strategies and demand across major geographic markets.

Additional coverage includes product-level sales forecasts, net present value analysis, market sizing, patient population estimates and opportunity assessments across siRNA and shRNA platforms. The study evaluates contract research organizations, contract manufacturing organizations and other service providers supporting RNAi therapeutic development and commercialization.

Industry insights were informed by discussions with senior executives, founders, chief executive officers, commercial leaders, technology specialists, medical executives and drug-delivery professionals from pharmaceutical and biotechnology companies in the United States and the United Kingdom.

Key Questions Addressed

Which companies lead the global RNAi therapeutics market?
Which regions and therapeutic areas offer the strongest growth opportunities?
What factors will influence market expansion through 2035?
What technical and commercial challenges affect RNAi developers?
How will market revenue be distributed by molecule, indication, administration route and geography?
Which delivery technologies and pipeline developments could reshape the competitive landscape?

The report is designed to support pharmaceutical companies, biotechnology developers, investors, distributors, channel partners and business development teams evaluating opportunities in the RNAi therapeutics market. It provides revenue forecasts, competitive intelligence, market-entry insights and strategic analysis to support investment, partnership and commercialization decisions.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Market Segmentations
1.4. Key Questions Answered
1.5. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Key Milestones and Historical Trends
6.2.1. Discovery of RNAi
6.2.2. RNAi Therapy Development Efforts
6.3. Mechanism of RNAi
6.3.1. Components of RNAi
6.3.2. Cellular Mechanism
6.4. Types of RNAi Molecules
6.4.1. siRNA
6.4.2. miRNA
6.4.3. shRNA
6.5. Applications of RNAi
6.5.1. Functional Genomics
6.5.2. Therapeutics
6.5.3. Biotechnology
6.5.4. Genome-scale Screening
6.6. Advantages and Disadvantages of RNAi
6.6.1. Advantages of RNAi
6.6.2. Disadvantages of RNAi
6.6.3. Case Study: Concerns Discussed During Regulatory Submissions in Clinic
6.7. Future Perspectives

7. MARKET OVERVIEW
7.1. Chapter Overview
7.2. RNAi Therapeutics: Marketed and Development Pipeline
7.2.1. Analysis by Type of RNAi Molecule
7.2.2. Analysis by Phase of Development
7.2.3. Analysis by Type of Molecule and Phase of Development
7.2.4. Analysis by Target Gene
7.2.5. Analysis by Therapeutic Area
7.2.6. Analysis by Route of Administration
7.2.7. RNAi Therapeutics: Special Designations
7.2.8. Key Players

8. COMPETITIVE LANDSCAPE
8.1. Chapter Overview
8.2. RNAi Therapeutics: Developer Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Location of Headquarters (Country-wise)
8.2.5. Key Players: Analysis by Number of Drug Candidates
8.3. RNAi Therapeutics: Regional Landscape

9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions / Key Parameters
9.3. Methodology
9.4. Company Competitive Analysis: RNAi Therapeutics Developers
9.5. Developers based in North America
9.6. Developers based in Europe
9.7. Developers based in Asia-Pacific

10. APPROVED AND LATE-STAGE RNAi THERAPEUTICS
10.1. Chapter Overview
10.2. Onpattro
10.2.1. Drug Overview
10.2.2. Technology Overview
10.2.3. Current Development Status
10.2.4. Recent Clinical Trial Results
10.2.5. Recent Partnerships
* Similar details are presented for other RNAi therapeutics mentioned below (based on information in the public domain)
10.3. Givlaari
10.4. Leqvio
10.5. Oxlumo
10.6. Fitusiran
10.7. Vutrisiran
10.8. Rivfloza
10.9. SYL 1001
10.10. SR-061

11. COMPANY PROFILES
11.1. Chapter Overview
11.2. Alnylam Pharmaceuticals
11.2.1. Company Overview
11.2.2. RNAi Therapeutics Portfolio
11.2.3. Management Team
11.2.4. Key Initiatives
* Similar details are presented for other RNAi therapeutics developers mentioned below (based on information in the public domain)
11.3. Arbutus Biopharma
11.4. Arrowhead Pharmaceuticals
11.5. Benitec Biopharma
11.6. Novo Nordisk
11.7. Novartis
11.8. OliX Pharmaceuticals
11.9. Silence Therapeutics

12. KEY THERAPEUTIC INDICATIONS
12.1. Chapter Overview
12.2. Oncological Disorders
12.2.1. Analysis by Target Indication and Phase of Development
12.2.2. Analysis by Type of RNAi Molecule
12.3. Infectious Diseases
12.3.1. Analysis by Target Indication and Phase of Development
12.3.2. Analysis by Type of RNAi Molecule
12.4. Metabolic Disorders
12.4.1. Analysis by Target Indication and Phase of Development
12.4.2. Analysis by Type of RNAi Molecule
12.5. Ophthalmic Diseases
12.5.1. Analysis by Target Indication and Phase of Development
12.5.2. Analysis by Type of RNAi Molecule
12.6. Genetic Disorders
12.6.1. Analysis by Target Indication and Phase of Development
12.6.2. Analysis by Type of RNAi Molecule

13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. RNAi Therapeutics: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Phase
13.3.3. Analysis by Trial Recruitment Status
13.3.4. Analysis by Type of Sponsor / Collaborator
13.3.5. Analysis by Type of RNAi Molecule and Trial Recruitment Status
13.3.6. Analysis by Therapeutic Area
13.3.7. Geographical Analysis by Number of Clinical Trials
13.3.8. Geographical Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
13.3.9. Geographical Analysis by Number of Clinical Trials and Type of RNAi Molecule
13.3.10. Geographical Analysis by Number of Clinical Trials, Type of RNAi Molecule and Trial Phase
13.3.11. Geographical Analysis by Number of Clinical Trials and Therapeutic Area
13.3.12. Geographical Analysis by Number of Clinical Trials, Therapeutic Area and Trial Phase
13.3.13. Geographical Analysis of Enrolled Patient Population by Location of Trial
13.3.14. Geographical Analysis of Enrolled Patient Population by Trial Phase and Trial Recruitment Status
13.3.15. Geographical Analysis of Enrolled Patient Population by Type of RNAi Molecule and Location of Trial
13.3.16. Geographical Analysis of Enrolled Patient Population by Type of RNAi Molecule, Trial Phase and Location of Trial
13.3.17. Geographical Analysis of Enrolled Patient Population by Therapeutic Area and Location of Trial
13.3.18. Geographical Analysis of Enrolled Patient Population by Therapeutic Area, Trial Phase and Location of Trial
13.4. Concluding Remarks
13.4.1. Key Therapeutic Candidates
13.4.2. Key Clinical Trials

14. KEY OPINION LEADERS
14.1. Chapter Overview
14.2. RNAi Therapeutics: Key Opinion Leaders
14.2.1. Analysis by Type of Organization
14.2.2. Analysis by Qualification
14.2.3. Analysis by Geographical Location of KOLs
14.2.4. Most Prominent Organizations: Analysis by Number of KOLs
14.2.5. KOL Activeness v/s KOL Strength
14.2.6. Most Prominent KOLs: Analysis by KOL Strength
14.2.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

15. PATENT ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. RNAi Therapeutics: Patent Analysis
15.3.1. Analysis by Publication Year
15.3.2. Analysis by Patent Type and Publication Year
15.3.3. Analysis by CPC Code
15.3.4. Analysis by Type of Applicant
15.3.5. Analysis by Geography
15.3.5.1. Analysis by Geography: North American Scenario
15.3.5.2. Analysis by Geography: European Scenario
15.3.5.3. Analysis by Geography: Asia-Pacific Scenario
15.3.6. Emerging Focus Areas
15.3.7. Leading Players: Analysis by Number of Patents
15.4. RNAi Therapeutics: Patent Benchmarking Analysis
15.4.1. Analysis by Key Patent Characteristics
15.4.1.1. Arrowhead Pharmaceuticals and Sirna Therapeutics
15.4.1.2. Other Leading Patent Assignees
15.5. RNAi Therapeutics: Patent Valuation Analysis

16. PUBLICATION ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Analysis by Year of Publication
16.4. Analysis by Type of Publication
16.5. Most Popular Keywords
16.6. Most Popular Journals: Analysis by Number of Publications
16.7. Most Popular Publisher: Analysis by Number of Publications
16.8. Most Popular Copyright Holders: Analysis by Number of Publications
16.9. Key Funding Institutes: Analysis by Number of Publications

17. PARTNERSHIPS AND COLLABORATIONS
17.1. Chapter Overview
17.2. Partnership Models
17.3. RNAi Therapeutics: Recent Partnerships and Collaborations
17.3.1. Analysis by Year of Partnership
17.3.2. Analysis by Type of Partnership
17.3.3. Analysis by Type of RNAi Molecule
17.3.4. Analysis by Scale of Partnership
17.3.5. Analysis by Therapeutic Area
17.3.6. Most Active Players: Analysis by Number of Partnerships
17.3.7. Regional Analysis
17.3.7.1. Country-wise Distribution
17.3.7.2. Intercontinental and Intracontinental Deals

18. FUNDING AND INVESTMENT ANALYSIS
18.1. Chapter Overview
18.2. Types of Funding
18.3. RNAi Therapeutics: Funding and Investment Analysis
18.3.1. Analysis by Cumulative Funding Instances, Since 2014
18.3.2. Analysis by Amount Invested
18.3.3. Analysis by Type of Funding
18.3.4. Analysis by Year and Type of Funding
18.3.5. Analysis of Amount Invested Across Different Types of RNAi Molecules
18.3.6. Regional Analysis by Amount Invested
18.3.7. Most Active Players
18.3.8. Key Investors
18.4. Concluding Remarks

19. KEY COMMERCIALIZATION STRATEGIES
19.1. Chapter Overview
19.2. Successful Drug Launch Strategy: Analyst's Framework
19.3. Successful Drug Launch Strategy: Product Differentiation
19.4. Commonly Adopted Commercialization Strategies based on Stage of Development of the Product
19.5. Approved RNAi Therapeutics
19.6. Key Commercialization Strategies Adopted by RNAi-based Therapy Developers
19.6.1. Strategies Adopted Before Therapy Approval
19.6.1.1. Participation in Global Events
19.6.1.1.1. Onpattro
19.6.1.1.2. Givlaari
19.6.1.1.3. Oxlumo
19.6.1.2. Collaboration with Stakeholders and Pharmaceutical Firms
19.6.1.2.1. Leqvio
19.6.1.3. Indication Expansion
19.6.1.3.1. Onpattro
19.6.1.3.2. Givlaari
19.6.1.3.3. Oxlumo
19.6.1.3.4. Leqvio
19.6.2. Strategies Adopted During / Post Therapy Approval
19.6.2.1. Participation in Global Events
19.6.2.1.1. Onpattro
19.6.2.1.2. Leqvio
19.6.2.2. Geographical Expansion
19.6.2.2.1. Onpattro
19.6.2.2.2. Givlaari
19.6.2.2.3. Oxlumo
19.6.2.2.4. Leqvio
19.6.2.3. Patient Assistance Programs
19.6.2.3.1. Onpattro
19.6.2.3.2. Givlaari
19.6.2.3.3. Oxlumo
19.6.2.4. Awareness Through Product Websites
19.6.2.5. Collaboration with Stakeholders and Pharmaceutical Firms
19.6.2.5.1. Onpattro
19.6.2.5.2. Givlaari
19.6.2.5.3. Oxlumo
19.6.2.5.4. Leqvio
19.6.2.6. Aligning with Government Initiatives to Ensure High Adoption Rate
19.6.2.6.1. Onpattro
19.6.2.6.2. Givlaari
19.6.2.6.3. Leqvio
19.7. Concluding Remarks

20. RNAi IN DIAGNOSTICS
20.1. Chapter Overview
20.2. Key Characteristics of Biomarkers
20.3. Circulating miRNA Biomarkers
20.4. miRNA Biomarkers in Oncological Disorders
20.4.1. Importance of Early Cancer Detection
20.4.2. Cancer Screening and Diagnosis
20.4.3. Conventional Cancer Diagnostics
20.4.3.1. Biopsy
20.4.4. Need for Non-Invasive Approaches
20.4.5. Key Indications
20.4.5.1. Breast Cancer
20.4.5.2. Colorectal Cancer
20.4.5.3. Gastric Cancer
20.4.5.4. Hematological Cancer
20.4.5.4.1. Acute Myeloid Leukemia
20.4.5.4.2. Lymphoma
20.4.5.5. Lung Cancer
20.4.5.6. Prostate Cancer
20.5. miRNA Biomarkers in Cardiovascular Diseases
20.5.1. Key Indications
20.5.1.1. Coronary Artery Disease
20.5.1.2. Myocardial Infarction
20.6. miRNA Based Diagnostic Tests

21. RNAi THERAPEUTICS SERVICE PROVIDERS
21.1. Chapter Overview
21.2. Analysis by Types of Service Providers
21.3. RNAi Therapeutics: List of CROs
21.3.1. Analysis by Year of Establishment
21.3.2. Analysis by Location of Headquarters
21.3.3. Analysis by Company Size
21.3.4. Analysis by Type of RNAi Molecule
21.4. RNAi Therapeutics: List of CMOs
21.4.1. Analysis by Year of Establishment
21.4.2. Analysis by Location of Headquarters
21.4.3. Analysis by Company Size
21.4.4. Analysis by Type of RNAi Molecule
21.5. RNAi Therapeutics: List of Consumables and Other Service Providers
21.5.1. Analysis by Year of Establishment
21.5.2. Analysis by Location of Headquarters
21.5.3. Analysis by Company Size
21.5.4. Analysis by Type of RNAi Molecule

22. DEMAND ANALYSIS
22.1. Chapter Overview
22.2. Methodology
22.3. Global Demand for RNAi Therapeutics, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
22.3.1. Analysis by Therapeutic Approach
22.3.2. Analysis by Target Therapeutic Area
22.3.3. Analysis by Route of Administration
22.3.4. Analysis by Key Players
22.3.5. Analysis by Geography

23. MARKET SIZING AND OPPORTUNITY ANALYSIS
23.1. Chapter Overview
23.2. Scope and Limitations
23.3. Key Assumptions and Forecast Methodology
23.4. Overall RNAi Therapeutics Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
23.4.1. RNAi Therapeutics Market: Analysis by Type of RNAi Molecule
23.4.2. RNAi Therapeutics Market: Analysis by Therapeutic Area
23.4.3. RNAi Therapeutics Market: Analysis by Route of Administration
23.4.4. RNAi Therapeutics Market: Share of Leading Players
23.4.5. RNAi Therapeutics Market: Analysis by Geography
23.5. RNAi Therapeutics Market: Value Creation Analysis
23.6. RNAi Therapeutics Market: Sales Forecasts
23.6.1. Onpattro
23.6.1.1. Target Patient Population
23.6.1.2. Sales Forecast
23.6.1.3. Net Present Value
23.6.1.4. Value Creation Analysis
23.6.2. GivlaariT
23.6.2.1. Target Patient Population
23.6.2.2. Sales Forecast
23.6.2.3. Net Present Value
23.6.2.4. Value Creation Analysis
23.6.3. Leqvio
23.6.3.1. Target Patient Population
23.6.3.2. Sales Forecast
23.6.3.3. Net Present Value
23.6.3.4. Value Creation Analysis
23.6.4. OxlumoT
23.6.4.1. Target Patient Population
23.6.4.2. Sales Forecast
23.6.4.3. Net Present Value
23.6.4.4. Value Creation Analysis
23.6.5. Fitusiran
23.6.5.1. Target Patient Population
23.6.5.2. Sales Forecast
23.6.5.3. Net Present Value
23.6.5.4. Value Creation Analysis
23.6.6. Vutrisiran
23.6.6.1. Target Patient Population
23.6.6.2. Sales Forecast
23.6.6.3. Net Present Value
23.6.6.4. Value Creation Analysis
23.6.7. SYL-1001
23.6.7.1. Target Patient Population
23.6.7.2. Sales Forecast
23.6.7.3. Net Present Value
23.6.7.4. Value Creation Analysis
23.6.8. Nedosiran
23.6.8.1. Target Patient Population
23.6.8.2. Sales Forecast
23.6.8.3. Net Present Value
23.6.8.4. Value Creation Analysis

24. SWOT ANALYSIS
24.1. Chapter Overview
24.2. Strengths
24.3. Weaknesses
24.4. Opportunities
24.5. Threats
24.6. Comparison of SWOT Factors
24.6.1. Concluding Remarks

25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Company A
25.2.1. Company Snapshot
25.2.2. Interview Transcript: Founder and Chief Executive Officer
25.3. Company B
25.3.1. Company Snapshot
25.3.2. Interview Transcript: President and Chief Executive Officer
25.4. Company C
25.4.1. Company Snapshot
25.4.2. Interview Transcript: President and Chief Executive Officer
25.5. Company D
25.5.1. Company Snapshot
25.5.2. Interview Transcript: Chief Executive Officer and Co-Founder
25.6. Company E
25.6.1. Company Snapshot
25.6.2. Interview Transcript: Chief Executive Officer
25.7. Company F
25.7.1. Company Snapshot
25.7.2. Interview Transcript: Senior Vice President, Head of International Region
25.8. Company G
25.8.1. Company Snapshot
25.8.2. Interview Transcript: Executive Vice President, Chief Commercial Officer
25.9. Company H
25.9.1. Company Snapshot
25.9.2. Interview Transcript: Chief Technology Officer and Head of US Operations
25.10. Company I
25.10.1. Company Snapshot
25.10.2. Interview Transcript: Former Chief Medical Officer
25.11. Company J
25.11.1. Company Snapshot
25.11.2. Interview Transcript: Head of Advanced Drug Delivery

26. CONCLUSION
26.1. Chapter Overview
26.2. Key Takeaways

27. APPENDIX 1: TABULATED DATA

List of Tables
Table 6.1 Merits and Demerits of RNAi Delivery Systems
Table 6.2 Comparison between siRNA, miRNA and shRNA
Table 7.1 RNAi Therapeutics: Marketed and Development Pipeline
Table 7.2 RNAi Therapeutics: Information on Special Drug Designation
Table 8.1 RNAi Therapeutics: List of Developers
Table 10.1 RNAi Therapeutics: List of Marketed and Approved Products
Table 10.2 Onpattro (Patisiran): Drug Overview
Table 10.3 Onpattro (Patisiran): Information on Completed and Active Clinical Trials
Table 10.4 Givlaari (ALN-AS1): Drug Overview
Table 10.5 Givlaari: Information on Completed and Active Clinical Trials
Table 10.6 Leqvio (Inclisiran): Drug Overview
Table 10.7 Leqvio (Inclisiran): Information on Completed and Active Clinical Trials
Table 10.8 Oxlumo (Lumasiran): Drug Overview
Table 10.9 Oxlumo (Lumasiran): Information on Completed and Active Clinical Trials
Table 10.10 Fitusiran (ALN-AT3): Drug Overview
Table 10.11 Fitusiran (ALN-AT3): Information on Completed and Active Clinical Trials
Table 10.12 Vutrisiran (ALN-TTRsc02): Drug Overview
Table 10.13 Vutrisiran (ALN-TTRsc02): Information on Completed and Active Clinical Trials
Table 10.14 Rivfloza: Drug Overview
Table 10.15 Rivfloza: Information on Completed and Active Clinical Trials
Table 10.16 SYL1001(Tivanisiran): Drug Overview
Table 10.17 SYL1001(Tivanisiran): Information on Completed and Active Clinical Trials
Table 10.18 SR-061: Drug Overview
Table 10.19 SR-061: Information on Completed and Active Clinical Trials
Table 13.1 Clinical Trial Analysis: Key Therapeutic Candidates
Table 13.2 Clinical Trial Analysis: Key Clinical Trials
Table 14.1 Key Opinion Leaders: List of Principal Investigators Involved in Clinical Trials
Table 15.1 Patent Analysis: CPC Code Definitions
Table 15.2 Patent Analysis: Most Popular CPC Codes
Table 15.3 Patent Analysis: List of Top CPC Codes
Table 15.4 Patent Analysis: Summary of Benchmarking Analysis
Table 15.5 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 16.1 RNAi Therapeutics: List of Publications
Table 17.1 RNAi Therapeutics: List of Partnerships, Since 2014
Table 18.1 RNAi Therapeutics: List of Funding and Investments, Since 2014
Table 18.2 Funding and Investment Analysis: Summary of Investments
Table 19.1 Onpattro: Presentations in Conferences Before Product Approval
Table 19.2 Givlaari: Presentations in Conferences Before Product Approval
Table 19.3 Oxlumo: Presentations in Conferences Before Product Approval
Table 19.4 Onpattro: Presentations in Conferences After Product Approval
Table 19.5 Leqvio: Presentations in Conferences Before Product Approval
Table 19.6 Approved RNAi Therapies: Patient Support Services Available on Product Websites (Comparative Analysis)
Table 19.7 Leqvio: Presentations in Conferences After Product Approval
Table 19.8 Approved RNAi Therapies: Patient Support Services Available on Product Websites (Comparative Analysis)
Table 20.1 Survival on Early Diagnosis of Cancer
Table 20.2 Cost of Biopsy for Different Cancer Indications (in USD)
Table 20.3 Breast Cancer: Reported miRNA Biomarkers
Table 20.4 Colorectal Cancer: Reported miRNA Biomarkers
Table 20.5 Gastric Cancer: Reported miRNA Biomarkers
Table 20.6 AML: Reported miRNA Biomarkers
Table 20.7 de novo DLBCL: Reported miRNA Biomarkers
Table 20.8 Lung Cancer: Reported miRNA Biomarkers
Table 20.9 Prostate Cancer: Reported miRNA Biomarkers
Table 20.10 Coronary Artery Disease: Reported miRNA Biomarkers
Table 20.11 Myocardial Infarction: Reported miRNA Biomarkers
Table 20.12 miRNA Diagnostic Tests: Pipeline
Table 21.1 RNAi Therapeutics: List of CROs
Table 21.2 RNAi Therapeutics: List of CMOs
Table 21.3 RNAi Therapeutics: List of Consumables Providers and Other Service Providers
Table 23.1 RNAi Therapeutics: Expected Launch Year of Advanced Stage Drug Candidates
Table 23.2 Onpattro: Target Patient Population
Table 23.3 Onpattro: Net Present Value (USD Million)
Table 23.4 Onpattro: Value Creation Analysis (USD Million)
Table 23.5 Givlaari: Target Patient Population
Table 23.6 Givlaari: Net Present Value (USD Million)
Table 23.7 Givlaari: Value Creation Analysis (USD Million)
Table 23.8 Leqvio: Target Patient Population
Table 23.9 Leqvio: Net Present Value (USD Million)
Table 23.10 Leqvio: Value Creation Analysis (USD Million)
Table 23.11 Oxlumo: Target Patient Population
Table 23.12 Oxlumo: Net Present Value (USD Million)
Table 23.13 Oxlumo: Value Creation Analysis (USD Million)
Table 23.14 Fitusiran: Target Patient Population
Table 23.15 Fitusiran: Net Present Value (USD Million)
Table 23.16 Fitusiran: Value Creation Analysis (USD Million)
Table 23.17 Vutrisiran: Target Patient Population
Table 23.18 Vutrisiran: Net Present Value (USD Million)
Table 23.19 Vutrisiran: Value Creation Analysis (USD Million)
Table 23.20 SYL 1001: Target Patient Population
Table 23.21 SYL 1001: Net Present Value (USD Million)
Table 23.22 SYL 1001: Value Creation Analysis (USD Million)
Table 23.23 Rivfloza: Target Patient Population
Table 23.24 Rivfloza: Net Present Value (USD Million)
Table 23.25 Rivfloza: Value Creation Analysis (USD Million)
Table 24.1 RNAi Therapeutics: SWOT Analysis
Table 24.2 Comparison of SWOT Factors: Harvey Ball Analysis
Table 26.1 Concluding Remarks: Market Overview
Table 26.2 Concluding Remarks: Competitive Landscape
Table 26.3 Concluding Remarks: Company Competitiveness Analysis
Table 26.4 Concluding Remarks: Technology Competitiveness Analysis
Table 26.5 Concluding Remarks: Clinical Trial Analysis
Table 26.6 Concluding Remarks: Key Opinion Leaders
Table 26.7 Concluding Remarks: Patent Analysis
Table 26.8 Concluding Remarks: Publication Analysis
Table 26.9 Concluding Remarks: Recent Partnerships
Table 26.10 Concluding Remarks: Funding and Investment Analysis
Table 26.11 Concluding Remarks: Demand Analysis
Table 26.12 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 27.1 RNAi Therapeutics: Distribution by Type of RNAi Molecule
Table 27.2 RNAi Therapeutics: Distribution by Phase of Development
Table 27.3 RNAi Therapeutics: Distribution by Type of RNAi Molecule and Phase of Development
Table 27.4 RNAi Therapeutics: Distribution by Target Gene
Table 27.5 RNAi Therapeutics: Distribution by Therapeutic Area
Table 27.6 RNAi Therapeutics: Distribution by Route of Administration
Table 27.7 RNAi Therapeutics: Distribution by Special Drug Designation
Table 27.8 RNAi Therapeutics: Distribution by Special Drug Designation and Therapeutic Area
Table 27.9 RNAi Therapeutics: Key Players
Table 27.10 RNAi Therapeutics Developers: Distribution by Year of Establishment
Table 27.11 RNAi Therapeutics Developers: Distribution by Company Size
Table 27.12 RNAi Therapeutics Developers: Distribution by Location of Headquarters (Continent-wise)
Table 27.13 RNAi Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
Table 27.14 RNAi Therapeutics Developers: Key Players
Table 27.15 RNAi Technology Platforms: Distribution by Purpose of Technology
Table 27.16 RNAi Technology Platforms: Distribution by Type of Molecule(s) Delivered
Table 27.17 RNAi Technology Platforms: Distribution by Type of Cell/ Tissue Targeted
Table 27.18 RNAi Technology Developers: Distribution by Year of Establishment
Table 27.19 RNAi Technology Developers: Distribution by Company Size
Table 27.20 RNAi Technology Developers: Distribution by Location of Headquarters (Continent-wise)
Table 27.21 RNAi Technology Developers: Distribution by Location of Headquarters (Country-wise)
Table 27.22 RNAi Therapeutics for Oncological Disorders: Distribution by Target Indication and Phase of Development
Table 27.23 RNAi Therapeutics for Oncological Disorders: Distribution by Type of RNAi Molecule
Table 27.24 RNAi Therapeutics for Infectious Diseases: Distribution by Target Indication and Phase of Development
Table 27.25 RNAi Therapeutics for Infectious Diseases: Distribution by Type of RNAi Molecule
Table 27.26 RNAi Therapeutics for Metabolic Disorders: Distribution by Target Indication and Phase of Development
Table 27.27 RNAi Therapeutics for Metabolic Disorders: Distribution by Type of RNAi Molecule
Table 27.28 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Target Indication and Phase of Development
Table 27.29 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Type of RNAi Molecule
Table 27.30 RNAi Therapeutics for Genetic Disorders: Distribution by Target Indication and Phase of Development
Table 27.31 RNAi Therapeutics for Genetic Disorders: Distribution by Type of RNAi Molecule
Table 27.32 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2014
Table 27.33 Clinical Trial Analysis: Distribution of Trials by Start Year and Type of Molecule, Since 2014
Table 27.34 Cumulative Distribution of Enrolled Patient Population by Study Start Year, Since 2014
Table 27.35 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 27.36 Clinical Trial Analysis: Distribution by Trial Recruitment Status and Phase of Development
Table 27.37 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 27.38 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Recruitment Status
Table 27.39 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Registration Year
Table 27.40 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Phase of Development
Table 27.41 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 27.42 Clinical Trial Analysis: Distribution by Therapeutic Area and Phase of Development
Table 27.43 Clinical Trial Analysis: Geographical Distribution of Clinical Trials
Table 27.44 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Recruitment Status
Table 27.45 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Type of RNAi Molecule
Table 27.46 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Type of RNAi Molecule
Table 27.47 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Therapeutic Area
Table 27.48 Geographical Analysis by Number of Clinical Trials, Therapeutic Area and Trial Phase
Table 27.49 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Table 27.50 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Recruitment Status
Table 27.51 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Type of RNAi Molecule
Table 27.52 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Type of RNAi Molecule
Table 27.53 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Table 27.54 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Therapeutic Area
Table 27.55 Key Opinion Leaders: Distribution by Type of Organization
Table 27.56 KOL Analysis: Distribution by Qualification
Table 27.57 KOL Analysis: Distribution by Geographical Location
Table 27.58 Most Prominent Organizations: Distribution by Number of KOLs
Table 27.59 Most Prominent KOLs: Distribution by KOL Strength
Table 27.60 Patent Analysis: Distribution by Type of Patent
Table 27.61 Patent Analysis: Cumulative Distribution by Publication Year, Since 2016
Table 27.62 Patent Analysis: Distribution by Patent Type and Publication Year
Table 27.63 Patent Analysis: Distribution by Type of Applicant
Table 27.64 Patent Analysis: Distribution by Geography
Table 27.65 Patent Analysis: North American Scenario
Table 27.66 Patent Analysis: European Scenario
Table 27.67 Patent Analysis: Asia-Pacific Scenario
Table 27.68 Leading Players (Industry): Distribution by Number of Patents
Table 27.69 Leading Players (Non-Industry): Distribution by Number of Patents
Table 27.70 Patent Analysis: Distribution by Patent Age, Since 2016
Table 27.71 Publication Analysis: Cumulative Year-wise Trend, Since 2016
Table 27.72 Publication Analysis: Distribution by Type of Publication
Table 27.73 Publication Analysis: Most Popular Keywords
Table 27.74 Top Journals: Distribution by Number of Publications
Table 27.75 Top Publishers: Distribution by Number of Publications
Table 27.76 Key Copyright Holders: Distribution by Number of Publications
Table 27.77 Key Funding Institutes: Distribution by Number of Publications
Table 27.78 Partnerships: Cumulative Year-Wise Trend, Since 2014
Table 27.79 Partnerships: Distribution by Type of Partnership
Table 27.80 Partnerships: Year-wise Trend by Type of Partnership
Table 27.81 Partnerships: Distribution by Type of RNAi Molecule
Table 27.82 Partnerships: Distribution by Scale of Partnership
Table 27.83 Partnerships: Distribution by Therapeutic Area
Table 27.84 Most Active Players: Distribution by Number of Partnerships
Table 27.85 Partnerships: Local and International Agreements
Table 27.86 Partnerships: Intercontinental and Intracontinental Distribution
Table 27.87 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment, Since 2014
Table 27.88 Funding and Investment Analysis: Cumulative Number of Instances by Year, Since 2014
Table 27.89 Funding and Investment Analysis: Cumulative Amount Invested, Since 2014 (USD Million)
Table 27.90 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2014
Table 27.91 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, Since 2014 (USD Million)
Table 27.92 Funding and Investments: Distribution of Number of Instances by Year and Type of Funding
Table 27.93 Funding and Investments: Distribution of Amount Invested across Different Types of RNAi Therapeutics
Table 27.94 Funding and Investment Analysis: Distribution by Geography
Table 27.95 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 27.96 Most Active Players: Distribution by Number of Instances, Since 2014
Table 27.97 Most Active Players: Distribution by Amount Invested, Since 2014 (USD Million)
Table 27.98 Key Investors: Distribution by Number of Instances
Table 27.99 RNAi Therapeutics: Types of Service Providers
Table 27.100 RNAi Therapeutic CROs: Distribution by Year of Establishment
Table 27.101 RNAi Therapeutics CROs: Distribution by Location of Headquarters
Table 27.102 RNAi Therapeutics CROs: Distribution by Company Size
Table 27.103 RNAi Therapeutics CROs: Distribution by Type of RNAi Molecule
Table 27.104 RNAi Therapeutics CMOs: Distribution by Year of Establishment
Table 27.105 RNAi Therapeutics CMOs: Distribution by Location of Headquarters
Table 27.106 RNAi Therapeutics CMOs: Distribution by Company Size
Table 27.107 RNAi Therapeutic Consumable Providers: Distribution by Year of Establishment
Table 27.108 RNAi Therapeutic Consumable Providers: Distribution by Location of Headquarters
Table 27.109 RNAi Therapeutic Consumable Providers: Distribution by Company Size
Table 27.110 RNAi Therapeutic Consumable Providers: Distribution by Type of RNAi Molecule
Table 27.111 Global Demand for RNAi Therapeutics, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (in terms of Target Patient Population)
Table 27.112 Demand Analysis: Distribution by Type of Molecule (in terms of Target Patient Population)
Table 27.113 Demand Analysis: Distribution by Therapeutic Area (in terms of Target Patient Population)
Table 27.114 Demand Analysis: Distribution by Route of Administration (in terms of Target Patient Population)
Table 27.115 Demand Analysis: Distribution by Key Players (in terms of Target Patient Population)
Table 27.116 Demand Analysis: Distribution by Geography (in terms of Target Patient Population)
Table 27.117 Overall RNAi Therapeutics Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 27.118 RNAi Therapeutics Market: Distribution by Type of RNAi Molecule (USD Million)
Table 27.119 RNAi Therapeutics Market: Distribution by Therapeutic Area (USD Billion)
Table 27.120 RNAi Therapeutics Market: Distribution by Route of Administration (USD Million)
Table 27.121 RNAi Therapeutics Market: Distribution by Share of Leading Players (USD Million)
Table 27.122 RNAi Therapeutics Market: Distribution by Geography (USD Billion)
Table 27.123 Onpattro Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.124 Givosiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.125 Inclisiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.126 Lumasiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.127 Fitusiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.128 Vutrisiran Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.129 SYL 1001 Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.130 Rivfloza Sales Forecast (Till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Competitive Landscape
Figure 5.3 Executive Summary: Technology Platforms and Delivery Systems
Figure 5.4 Executive Summary: Clinical Trial Analysis
Figure 5.5 Executive Summary: Patent Analysis
Figure 5.6 Executive Summary: Publication Analysis
Figure 5.7 Executive Summary: Partnerships and Collaborations
Figure 5.8 Executive Summary: Funding and Investment Analysis
Figure 5.9 Executive Summary: Demand Analysis
Figure 5.10 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 RNA Interference: Key Milestones and Historical Evolution
Figure 6.2 RNA Interference: Key Components
Figure 6.3 RNA Interference: Working Mechanism
Figure 6.4 RNA Interference: Types of Delivery Systems
Figure 6.5 RNA Interference: Advantages and Disadvantages
Figure 7.1 RNAi Therapeutics: Distribution by Type of RNAi Molecule
Figure 7.2 RNAi Therapeutics: Distribution by Phase of Development
Figure 7.3 RNAi Therapeutics: Distribution by Molecule and Phase of Development
Figure 7.4 RNAi Therapeutics Pipeline: Distribution by Target Gene
Figure 7.5 RNAi Therapeutics Pipeline: Distribution by Therapeutic Area
Figure 7.6 RNAi Therapeutics Pipeline: Distribution by Route of Administration
Figure 7.7 RNAi Therapeutics: Distribution by Special Drug Designation
Figure 7.8 RNAi Therapeutics: Distribution by Special Drug Designation and Therapeutic Area
Figure 7.9 RNAi Therapeutics: Key Players
Figure 8.1 RNAi Therapeutics Developers: Distribution by Year of Establishment
Figure 8.2 RNAi Therapeutics Developers: Distribution by Company Size
Figure 8.3 RNAi Therapeutics Developers: Distribution by Location of Headquarters
Figure 8.4 RNAi Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
Figure 8.5 RNAi Therapeutics Developers: Key Players
Figure 8.6 RNAi Therapeutics Developers: Regional Landscape
Figure 9.1 Company Competitiveness Analysis: Developers based in North America
Figure 9.2 Company Competitiveness Analysis: Developers based in Europe
Figure 9.3 Company Competitiveness Analysis: Developers based in Asia-Pacific
Figure 10.1 Onpattro (Alnylam Pharmaceuticals): Timeline of Regulatory Approvals Across Regions
Figure 10.2 Lipid Nanoparticles Delivery System: Mode of Action
Figure 10.3 Givlaari (Alnylam Pharmaceuticals): Timeline of Regulatory Approvals Across Regions
Figure 10.4 ESC-GalNAc Delivery System: Mode of Action
Figure 10.5 Leqvio (Alnylam Pharmaceuticals): Timeline of Regulatory Approvals Across Regions
Figure 12.1 RNAi Therapeutics for Oncological Disorders: Distribution by Target Indication and Phase of Development
Figure 12.2 RNAi Therapeutics for Oncological Disorders: Distribution by Type of RNAi Molecule
Figure 12.3 RNAi Therapeutics for Infectious Diseases: Distribution by Target Indication and Phase of Development
Figure 12.4 RNAi Therapeutics for Infectious Diseases: Distribution by Type of RNAi Molecule
Figure 12.5 RNAi Therapeutics for Metabolic Disorders: Distribution by Target Indication and Phase of Development
Figure 12.6 RNAi Therapeutics for Metabolic Disorders: Distribution by Type of RNAi Molecule
Figure 12.7 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Target Indication and Phase of Development
Figure 12.8 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Type of RNAi Molecule
Figure 12.9 RNAi Therapeutics for Genetic Disorders: Distribution by Target Indication and Phase of Development
Figure 12.10 RNAi Therapeutics for Genetic Disorders: Distribution by Type of RNAi Molecule
Figure 13.1 Clinical Trial Analysis: Methodology
Figure 13.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2014
Figure 13.3 Clinical Trial Analysis: Distribution of Trials by Start Year and Type of Molecule, Since 2014
Figure 13.4 Clinical Trial Analysis: Cumulative Distribution of Enrolled Patient Population by Study Start Year, Since 2014
Figure 13.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.6 Clinical Trial Analysis: Distribution by Trial Recruitment Status and Phase of Development
Figure 13.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 13.8 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Recruitment Status
Figure 13.9 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Registration Year
Figure 13.10 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Phase of Development
Figure 13.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 13.12 Clinical Trial Analysis: Distribution by Therapeutic Area and Phase of Development
Figure 13.13 Clinical Trial Analysis: Geographical Distribution of Clinical Trials
Figure 13.14 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Recruitment Status
Figure 13.15 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Type of RNAi Molecule
Figure 13.16 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Type of RNAi Molecule
Figure 13.17 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Therapeutic Area
Figure 13.18 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Therapeutic Area
Figure 13.19 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Figure 13.20 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Recruitment Status
Figure 13.21 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Type of RNAi Molecule
Figure 13.22 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Type of RNAi Molecule
Figure 13.23 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Figure 13.24 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Therapeutic Area
Figure 14.1 KOL Analysis: Distribution by Type of Organization
Figure 14.2 KOL Analysis: Distribution by Qualification
Figure 14.3 KOL Analysis: Distribution by Geographical Location
Figure 14.4 Most Prominent Organizations: Distribution by Number of KOLs
Figure 14.5 Scatter Plot: KOL Activeness v/s KOL Strength
Figure 14.6 Most Prominent KOLs: Distribution by KOL Strength
Figure 14.7 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 14.8 Linear Regression Analysis: Comparison of RA Score with Third-Party Score
Figure 14.9 Most Prominent KOLs: KOL Activeness v/s KOL Strength
Figure 15.1 Patent Analysis: Distribution by Type of Patent
Figure 15.2 Patent Analysis: Cumulative Distribution by Publication Year, Since 2016
Figure 15.3 Patent Analysis: Distribution by Patent Type and Publication Year
Figure 15.4 Patent Analysis: Distribution by CPC Symbols
Figure 15.5 Patent Analysis: Distribution by Type of Applicant
Figure 15.6 Patent Analysis: Distribution by Geography
Figure 15.7 Patent Analysis: North American Scenario
Figure 15.8 Patent Analysis: European Scenario
Figure 15.9 Patent Analysis: Asia-Pacific Scenario
Figure 15.10 Patent Analysis: Emerging Focus Areas
Figure 15.11 Leading Players (Industry): Distribution by Number of Patents
Figure 15.12 Leading Players (Non-Industry): Distribution by Number of Patents
Figure 15.13 Patent Analysis: Benchmarking by Patent Characteristics
Figure 15.14 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics
Figure 15.15 Patent Analysis: Distribution by Patent Age, Since 2016
Figure 15.16 Patent Analysis: Categorizations based on Weighted Valuation Scores
Figure 15.17 Patent Analysis: Patent Valuation
Figure 16.1 Publication Analysis: Cumulative Year-wise Trend, Since 2016
Figure 16.2 Publication Analysis: Distribution by Type of Publication
Figure 16.3 Publication Analysis: Most Popular Keywords
Figure 16.4 Most Popular Journals: Distribution by Number of Publications
Figure 16.5 Most Popular Publishers: Distribution by Number of Publications
Figure 16.6 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 16.7 Key Funding Institutes: Distribution by Number of Publications
Figure 17.1 Partnerships: Cumulative Year-Wise Trend, Since 2014
Figure 17.2 Partnerships: Distribution by Type of Partnership
Figure 17.3 Partnerships: Year-wise Trend by Type of Partnership
Figure 17.4 Partnerships: Distribution by Type of RNAi Molecule
Figure 17.5 Partnerships: Distribution by Scale of Partnership
Figure 17.6 Partnerships: Distribution by Therapeutic Area
Figure 17.7 Most Active Players: Distribution by Number of Partnerships
Figure 17.8 Partnerships: Local and International Agreements
Figure 17.9 Partnerships: Intercontinental and Intracontinental Distribution
Figure 18.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment, Since 2014
Figure 18.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, Since 2014
Figure 18.3 Funding and Investment Analysis: Cumulative Amount Invested, Since 2014 (USD Million)
Figure 18.4 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, Since 2014
Figure 18.5 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2014
Figure 18.6 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, Since 2014 (USD Million)
Figure 18.7 Funding and Investments: Distribution of Number of Instances by Year and Type of Funding
Figure 18.8 Funding and Investments: Distribution by Amount Invested across Different Types of RNAi Therapeutics
Figure 18.9 Funding and Investment Analysis: Distribution by Geography
Figure 18.10 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 18.11 Most Active Players: Distribution by Number of Instances, Since 2014
Figure 18.12 Most Active Players: Distribution by Amount Invested, Since 2014 (USD Million)
Figure 18.13 Key Investors: Distribution by Number of Instances
Figure 18.14 Funding and Investment Summary, Since 2014 (USD Million)
Figure 19.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 19.2 Successful Drug Launch Strategy: Product Differentiation
Figure 19.3 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 19.4 Harvey Ball Analysis: Commercialization Strategies Adopted by RNAi-Based Therapy Developers
Figure 19.5 Approved RNAi Therapies: Snapshot of Promotional Activities on Product Websites
Figure 19.6 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Figure 20.1 Circulating miRNA Biomarkers: Key Criteria
Figure 20.2 Factors Determining Useful Cancer Screening
Figure 20.3 Conventional Methods for Cancer Diagnosis
Figure 21.1 RNAi Therapeutics: Types of Service Providers
Figure 21.2 RNAi Therapeutic CROs: Distribution by Year of Establishment
Figure 21.3 RNAi Therapeutics CROs: Distribution by Location of Headquarters
Figure 21.4 RNAi Therapeutics CROs: Distribution by Company Size
Figure 21.5 RNAi Therapeutics CMOs: Distribution by Year of Establishment
Figure 21.6 RNAi Therapeutics CMOs: Distribution by Location of Headquarters
Figure 21.7 RNAi Therapeutics CMOs: Distribution by Company Size
Figure 21.8 RNAi Therapeutic Consumable Providers: Distribution by Year of Establishment
Figure 21.9 RNAi Therapeutic Consumable Providers: Distribution by Location of Headquarters
Figure 21.10 RNAi Therapeutic Consumable Providers: Distribution by Company Size
Figure 22.1 Global Demand for RNAi Therapeutics, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (in terms of Target Patient Population)
Figure 22.2 Demand Analysis: Distribution by Type of Molecule (in terms of Target Patient Population)
Figure 22.3 Demand Analysis: Distribution by Therapeutic Area (in terms of Target Patient Population)
Figure 22.4 Demand Analysis: Distribution by Route of Administration (in terms of Target Patient Population)
Figure 22.5 Demand Analysis: Distribution by Key Players (in terms of Target Patient Population)
Figure 22.6 Demand Analysis: Distribution by Geography (in terms of Target Patient Population)
Figure 23.1 Overall RNAi Therapeutics Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035): Base Scenario (USD Billion)
Figure 23.2 RNAi Therapeutics Market: Distribution by Type of RNAi Molecule (USD Million)
Figure 23.3 RNAi Therapeutics Market: Distribution by Therapeutic Area (USD Billion)
Figure 23.4 RNAi Therapeutics Market: Distribution by Route of Administration (USD Million)
Figure 23.5 RNAi Therapeutics Market: Distribution by Share of Leading Players (USD Million)
Figure 23.6 RNAi Therapeutics Market: Distribution by Geography
Figure 23.7 Onpattro Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 23.8 Givosiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 23.9 Inclisiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 23.10 Lumasiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 23.11 Fitusiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 23.12 Vutrisiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 23.13 SYL 1001 Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 23.14 Nedosiran Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 24.1 RNAi Therapeutics: SWOT Analysis
Figure 24.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 26.1 Concluding Remarks: Market Overview
Figure 26.2 Concluding Remarks: Competitive Landscape
Figure 26.3 Concluding Remarks: Company Competitiveness Analysis
Figure 26.4 Concluding Remarks: Technology Platforms and Delivery Systems
Figure 26.5 Concluding Remarks: Technology Competitiveness Analysis
Figure 26.6 Concluding Remarks: Clinical Trial Analysis
Figure 26.7 Concluding Remarks: Key Opinion Leaders
Figure 26.8 Concluding Remarks: Patent Analysis
Figure 26.9 Concluding Remarks: Publication Analysis
Figure 26.10 Concluding Remarks: Recent Partnerships
Figure 26.11 Concluding Remarks: Funding and Investment Analysis
Figure 26.12 Concluding Remarks: Key Commercialization Strategies
Figure 26.13 Concluding Remarks: Demand Analysis
Figure 26.14 Concluding Remarks: Market Sizing and Opportunity Analysis (1/2)
Figure 26.15 Concluding Remarks: Market Sizing and Opportunity Analysis (2/2)

A selection of companies mentioned in this report includes, but is not limited to:

Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
Benitec Biopharma
Novo Nordisk
Novartis
OliX Pharmaceuticals
Silence Therapeutics
Sirnaomics

For more information about this report visit https://www.researchandmarkets.com/r/5o76i4

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900

2026 RNAi Therapeutics Market Report (3rd Edition): Analysis by Type of RNAi Molecule, Therapeutic Area, Route of Administration, Key Geographical Regions, Sales Forecast and Leading Industry Players to 2035